Showing 301-310 of 4902 results for "".
- Gary D. Monheit, MD Wins Top ASDS Honorhttps://practicaldermatology.com/news/gary-d-monheit-md-wins-top-asds-honor/2459040/Gary D. Monheit, MD is the “very honored” 2014 recipient of the American Society for Dermatologic Surgery's highest honor: the Samuel J. Stegman, MD, Award for D
- Dr. Kevin Pinski Presents Injectable Pearls at Noahhttps://practicaldermatology.com/news/dr-kevin-pinski-presents-injectable-pearls-at-noah/2486902/At the 67th Noah Worcester Dermatological Society Annual Meeting, Kevin Pinski, MD, presented “Injectable Pearls,” drawing on nearly 4 decades of experience with neuromodulators, fillers, and cosmetic injectables. The presentation covered practical techniques, pati
- New CFO at Evolus, Inc.https://practicaldermatology.com/news/new-cfo-at-evolus-inc/2457744/Lauren Silvernail is the new Chief Financial Officer and Executive Vice President, Corporate Development at Evolus, Inc. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance The
- FDA Approves ZELSUVMI™ as a First-in-Class Medication for Molluscum Contagiosumhttps://practicaldermatology.com/news/fda-approves-zelsuvmi-as-a-first-in-class-medication-for-molluscum-contagiosum/2462203/Ligand Pharmaceuticals Inc
- New Kerecis Medical-Fish-Skin Product Approved by Medicare Administrative Contractorshttps://practicaldermatology.com/news/new-kerecis-medical-fish-skin-product-approved-by-medicare-administrative-contractors/2461961/Multiple leading Medicare Administrative Contractors have approved Kerecis Shield, the new fish-skin wound-treatment product. This means that physicians in private clinics will not need to submit invoices for reimbursement, improving efficiency by eliminating a step in the reimbursement proc
- Dupixent Update: Medication Shows Promise in Five Inflammatory Diseaseshttps://practicaldermatology.com/news/dupixent-update-medication-shows-promise-in-five-inflammatory-diseases/2461063/Dupixent (dupilumab) performed well across five diseases with underlying type 2 inflammation. The five diseases include eosinophilic esophagitis, chronic spontaneous urticaria, asthma, chronic rhinosinusitis with nasal polyposis, and atopic dermatitis. Additionally, positive result
- Simulation Techniques Help Medical Students Empathize with Melanoma Patientshttps://practicaldermatology.com/news/simulation-techniques-help-medical-students-empathize-with-melanoma-patients/2458110/Simulation techniques can allow doctors to experience what it feels like to be a melanoma patient. The study, which is led by Queen’s University in Belfast collaboration with researchers from the University of Huddersfield and University College Dublin, appears in the
- AAD, Other Major Medical Associations Support March For Sciencehttps://practicaldermatology.com/news/aad-other-major-medical-associations-support-march-for-science/2458214/The American Academy of Dermatology is joining up with many leading organizations in support of the March for Science and its nonpartisan call for the appreciation of scientific evidence, education, and investment. There are close to
- Zeltiq Named Top Medical Devices Company in Deloitte's Technology Fast 500™https://practicaldermatology.com/news/20141117-zeltiq_named_top_medical_devices_company_in__deloittes_technology_fast_500/2459063/Ranked among the top 25 companies in Deloitte's Technology Fast 500™ ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America, Zeltiq Aesthetics, Inc. is the top ranked
- Cynosure Acquires Assets of RF Medical Device Manufacturer Ellman International, Inc.https://practicaldermatology.com/news/20140910-cynosure_acquires_assets_of_rf_medical_device_manufacturer_ellman_international_inc/2459121/Cynosure, Inc., which specializes in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, has acquired the assets of Ellman International, Inc. for approximately $13.2 million in cash. In addition, Cynosure assumed certain contractual and current liab